Analysis of Two Oncological Drugs Futibatinib and Capivasertib via Ion-Pairing With Eosin Y as a Spectrofluorimetric and Spectrophotometric Probe.

Publisher: Wiley & Sons Country of Publication: England NLM ID: 100889025 Publication Model: Print Cited Medium: Internet ISSN: 1522-7243 (Electronic) Linking ISSN: 15227235 NLM ISO Abbreviation: Luminescence Subsets: MEDLINE

Original Publication: Chichester, Sussex, UK : Wiley & Sons, c1999-

Antineoplastic Agents*/chemistry ; Antineoplastic Agents*/analysis ; Spectrometry, Fluorescence* ; Eosine Yellowish-(YS)*/chemistry; Spectrophotometry ; Hydrogen-Ion Concentration ; Fluorescent Dyes/chemistry ; Molecular Structure

Using spectroscopy, two quick and sensitive analytical methods based on eosin Y ion pairing were developed and assessed in order to determine capivasertib and futibatinib with high selectivity and sensitivity. The quenching impact of futibatinib or capivasertib on the eosin Y's fluorescence at a pH 3.8 and 3.3 for futibatinib and capivasertib, respectively, in 0.1-M acetate buffer solution was observed using two spectrofluorometric techniques. These techniques are regarded as the original spectrofluorometric techniques for the assay of futibatinib and capivasertib. For futibatinib and capivasertib, the quenching effect on fluorescence was ranged from 100 to 1000 and 150 to 1500 ng mL ^-1 , respectively. The absorbance of the generated ion-pair was measured using two different spectrophotometric methods at 550 nm in aqueous buffered solutions with pH values of 3.8 and 3.3 for futibatinib and capivasertib, respectively. In the concentration range of 1.0-10.0 and 2.0-10.0 μg mL ^-1 , Beer's law was followed. The four approaches were applied to the analysis of dosage forms with a high percent recovery successfully, and they were assessed in compliance with ICH guidelines.
(© 2024 John Wiley & Sons Ltd.)

A. Kommalapati, S. H. Tella, M. Borad, M. Javle, and A. Mahipal, “FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice,” Cancers 13 (2021): 2968.
H. Sootome, H. Fujita, K. Ito, et al., “Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity Against FGFR‐Deregulated Tumors,” Cancer Research 80 (2020): 4986–4997.
F.O.U. FDA Approved Drug Products: LYTGOBI (futibatinib) Tablets.
C. Powers, S. McLeskey, and A. Wellstein, “Fibroblast Growth Factors, Their Receptors and Signaling,” Endocrine‐Related Cancer 7 (2000): 165–197.
P. C. Lee, A. Hendifar, A. Osipov, M. Cho, D. Li, and J. Gong, “Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations,” Cancers 13 (2021): 1706.
G. King and M. Javle, “FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma,” Current Oncology Reports 23 (2021): 1–13.
G. Aitcheson, A. Mahipal, and B. V. John, “Targeting FGFR in Intrahepatic Cholangiocarcinoma [iCCA]: Leading the Way for Precision Medicine in Biliary Tract Cancer [BTC]?” Expert Opinion on Investigational Drugs 30 (2021): 463–477.
L. Chen, Y. Zhang, L. Yin, et al., “Fibroblast Growth Factor Receptor Fusions in Cancer: Opportunities and Challenges,” Clinical Trials 40 (2021): 1–15.
A. Rizzo, A. D. Ricci, and G. Brandi, “Futibatinib, an Investigational Agent for the Treatment of Intrahepatic Cholangiocarcinoma: Evidence to Date and Future Perspectives,” Expert Opinion on Investigational Drugs 30 (2021): 317–324.
F. Meric‐Bernstam, R. Bahleda, C. Hierro, et al., “Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose‐Expansion Study,” Cancer Discovery 12 (2022): 402–415.
R. Bahleda, F. Meric‐Bernstam, L. Goyal, et al., “Phase I, First‐In‐Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients With Advanced Solid Tumors,” Annals of Oncology 31, no. 10 (2020): 1405–1412.
H. Li, H.‐Z. Ding, Y.‐L. Wang, F. Zhang, Y.‐H. Song, and X.‐J. Qiu, “Validated UPLC‐MS/MS Method for Determination of Futibatinib and Its Pharmacokinetics in Beagle Dogs,” Journal of Chemistry 2022 (2022): 1–7.
L. W. T. Tang and E. C. Y. Chan, “Quantification of the Irreversible Fibroblast Growth Factor Receptor Inhibitor Futibatinib by UPLC‐MS/MS: Application to the Metabolic Stability Assay in Human Liver Microsomes for the Estimation of Its in Vitro Hepatic Intrinsic Clearance,” Journal of Pharmaceutical and Biomedical Analysis 214 (2022): 114731.
B. R. Davies, H. Greenwood, P. Dudley, et al., “Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity With Genetic Background,” Molecular Cancer Therapeutics 11 (2012): 873–887.
D. Sarker, A. H. Reid, T. A. Yap, and J. S. De Bono, “Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer,” Clinical Cancer Research 15 (2009): 4799–4805.
P. J. Kaboli, F. Salimian, S. Aghapour, et al., “Akt‐Targeted Therapy as a Promising Strategy to Overcome Drug Resistance in Breast Cancer—A Comprehensive Review From Chemotherapy to Immunotherapy,” Pharmacological Research 156 (2020): 104806.
N. E. Uko, O. F. Güner, D. F. Matesic, and J. P. Bowen, “Akt Pathway Inhibitors,” Current Topics in Medicinal Chemistry 20 (2020): 883–900.
Z. Zhang, L. Nong, M. L. Chen, M. H. Liu, and W. W. Cheng, “A Validated LC‐MS/MS Method for the Quantification of Capivasertib in Dog Plasma: Application to Its Pharmacokinetics Study,” Biomedical Chromatography 34 (2020): e4920.
A. A. Sakur and D. A. Zakri, “A New Selective Colorimetric Method Coupled With a High‐Resolution UV Method for the Consecutive Quantification of Three Drugs in Semi‐Solid Preparations,” Heliyon 8 (2022): e11003.
M. Tolba and M. Salim, “Insights for Applying Erythrosine B as a Green Fluorescence Probe for Estimation of Anticancer Tamoxifen and Its Analog; Clomiphene in Nanogram Concentration,” Spectrochimica Acta Part A: Molecular Biomolecular Spectroscopy 263 (2021): 120156.
A. A. Hamad, R. Ali, and S. M. Derayea, “A Simple Single Jar “On–Off Fluorescence” Designed System for the Determination of Mitoxantrone Using an Eosin Y Dye in raw Powder, Vial, and Human Biofluids,” RSC Advances 12 (2022): 7413–7421.
S. M. Derayea and D. M. Nagy, “Application of a Xanthene Dye, Eosin Y, as Spectroscopic Probe in Chemical and Pharmaceutical Analysis; a Review,” Reviews in Analytical Chemistry 37 (2018): 20170020.
H. Salem, M. A. Omar, D. Z. Mazen, and D. A. M. Nour El‐Deen, “Utilization of a Complex Arrangement Approach for Spectroscopic Examination With Eosin Y of Various Cephalosporins in Their Pure or Pharmaceutical Dosage Forms, and in Human Plasma,” Luminescence 36 (2021): 1572–1583.
H. Salem, A. Abdelaziz, S. Derayea, D. M. Nagy, and K. M. Badr El‐Din, “Spectrofluorimetric Assay of Amlodipine and Perindopril in Their Raw Materials, Pharmaceutical Formulations and Spiked Human Plasma Through the Formation of Complexes With Eosin Y,” Chemical Papers 77 (2023): 2817–2825.
J. Płotka‐Wasylka, “A new Tool for the Evaluation of the Analytical Procedure: Green Analytical Procedure Index,” Talanta 181 (2018): 204–209.
F. Pena‐Pereira, W. Wojnowski, and M. Tobiszewski, “AGREE—Analytical GREEnness Metric Approach and Software,” Analytical Chemistry 92 (2020): 10076–10082.
C. Y. Huang, “Determination of Binding Stoichiometry by the Continuous Variation Method: The Job Plot,” Methods in Enzymology 87 (1982): 509–525, https://doi.org/10.1016/s0076‐6879(82)87029‐8.
ICH, Q2 (R1): Validation of Analytical Procedures; Text and Methodology (Geneva: International Conference on Harmonization, 2005).
H. Salem, A. Abdelaziz, M. R. Mekawy, et al., “Utility of Green Chemistry for Native Spectrofluorimetric Quantification of Darolutamide as a Modern Anti‐Neoplastic Drug in Its Market Form and Biological Fluids,” RSC Advances 12 (2022): 10198–10203.
H. Salem, E. Samir, M. Galal, M. Hussien, and A. Abdelaziz, “Green‐Sensitive Spectrofluorimetric Determination of Pemetrexed as an Antineoplastic Drug: Application in Pharmaceutical Dosage Forms and Spiked Human Plasma,” Luminescence 38 (2023): 64–70.
H. Salem, N. Abdal‐Karim, B. Omran, et al., “Green Chemistry Method Based on Native Fluorescence for Estimation of Recently Approved Anti‐Neoplastic Drug Sotorasib,” Analytical Chemistry Letters 12 (2022): 2230.
H. Salem, D. Z. Mazen, N. Emad, H. Hassan, B. Omran, and M. A. Abdelmajed, “Green Micellar Spectrofluorimetric Determination of α‐Mangostin as Antioxidant and Other Biological Activities Beneficial to Human Health Found in Herbal Products,” Luminescence 38 (2023): 672–679.
H. Salem, A. Abdelaziz, M. Galal, et al., “Synchronous Fluorescence as a Green and Selective Method for the Simultaneous Determination of Finasteride and Tadalafil in Dosage Form and Spiked Human Plasma,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 299 (2023): 122838.
H. Salem, J. Fares, H. Ahmed, and A. Abdelaziz, “Utility of Green Chemistry for Sustainable Fluorescence Derivatization Approach for Quantification of Fingolimod as Antineoplastic Drug in Pharmaceutical Formulation and Spiked Human Plasma,” Green Analytical Chemistry 8 (2024): 100104.

Keywords: capivasertib; eosin Y; futibatinib; pharmaceutical formulations; spectrofluorimetry; spectrophotometry

0 (Antineoplastic Agents)
TDQ283MPCW (Eosine Yellowish-(YS))
0 (Fluorescent Dyes)

Date Created: 20241014 Date Completed: 20241014 Latest Revision: 20241014

20241015

10.1002/bio.4919

39400514